LLY

901.63

-2.46%↓

JNJ

234.48

-0.42%↓

ABBV

205.7

+0.47%↑

NVS

148.48

+0.05%↑

AZN

184.99

-0.21%↓

LLY

901.63

-2.46%↓

JNJ

234.48

-0.42%↓

ABBV

205.7

+0.47%↑

NVS

148.48

+0.05%↑

AZN

184.99

-0.21%↓

LLY

901.63

-2.46%↓

JNJ

234.48

-0.42%↓

ABBV

205.7

+0.47%↑

NVS

148.48

+0.05%↑

AZN

184.99

-0.21%↓

LLY

901.63

-2.46%↓

JNJ

234.48

-0.42%↓

ABBV

205.7

+0.47%↑

NVS

148.48

+0.05%↑

AZN

184.99

-0.21%↓

LLY

901.63

-2.46%↓

JNJ

234.48

-0.42%↓

ABBV

205.7

+0.47%↑

NVS

148.48

+0.05%↑

AZN

184.99

-0.21%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

23.13 -1.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.73

Máximo

23.69

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	13.869 57.833
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+47.94% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-100M 2.9B
Apertura anterior	24.16
Cierre anterior	23.13

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

67 / 350 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

47.94% repunte

Estimación a 12 Meses

Media 34.5 USD 47.94%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

67 / 350 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.